SCHEMBL3572843

SCHEMBL3572843

Cc1ccc(/C(=C2\CC(C)(C)CC(C)C2C)c2ccccc2)cc1OCC(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 6/20 0.40
L3MBTL1 Q9Y468 3/20 0.39
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.35
POLB P06746 1/20 0.35
GLA P06280 1/20 0.35
KDM4E B2RXH2 1/20 0.35
PPARG P37231 2/20 0.34
PPARD Q03181 2/20 0.34
PPARA Q07869 1/20 0.34
NPC1 O15118 1/20 0.34
MITF O75030 1/20 0.34
NFKB1 P19838 1/20 0.34
RAB9A P51151 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
PAX8 Q06710 1/20 0.34
KLF5 Q13887 1/20 0.34
ATM Q13315 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3572844 1.00 PTGDR2 (0.40) PTGDR2L3MBTL1MEN1KMT2ASMN1; SMN2
SCHEMBL3074996 0.79 PTGDR2 (0.44) PTGDR2L3MBTL1MEN1KMT2ASMN1; SMN2
SCHEMBL3078835 0.68 TSHR (0.53) L3MBTL1MEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL3073700 0.65 GAA (0.35) L3MBTL1SMN1; SMN2KDM4EPPARGPPARA
SCHEMBL4384639 0.64 PKM (0.61) PTGDR2L3MBTL1SMN1; SMN2POLBGLA
SCHEMBL3078288 0.64 APOBEC3A (0.39) L3MBTL1MEN1KMT2APOLBRAB9A
SCHEMBL3064143 0.64 TSHR (0.70) PTGDR2MEN1KMT2ASMN1; SMN2POLB
SCHEMBL3080491 0.64 ALDH1A1 (0.33) MEN1KMT2ASMN1; SMN2POLB
SCHEMBL654774 0.64 SMN1; SMN2 (0.67) PTGDR2L3MBTL1MEN1KMT2ASMN1; SMN2
SCHEMBL29966790 0.64 SMN1; SMN2 (0.67) PTGDR2L3MBTL1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723393-B2 Cycloalkylidene compounds as selective estrogen receptor modulators GLAXOSMITHKLINE LLC (US) 2010-05-25 US disclosed
US-20080167360-A1 Cycloalkylidene Compounds as Selective Estrogen Receptor Modulators SMITHKLINE BEECHAM CORPORATION 2008-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167360-A1 Cycloalkylidene Compounds as Selective Estrogen Receptor Modulators GPER1, ESR2, ESRRG PTGDR2 27/4885L3MBTL1 4862/4885MEN1 4274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.